Propanc Biopharma Inc (PPCB)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 0 0 0 0
Cost of Revenue 0 4,332 5,534 5,764
Gross Profit 0 0 0 -5,764
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 0 158,994 229,076 207,509
Operating Expenses 53,128,713 209,050 285,256 254,135
Operating Income -53,128,713 -213,382 -290,790 -259,899
Interest Expense -104,042 118,943 86,230 90,004
Income Before Tax -54,067,346 -430,183 -354,310 -358,815
Income Tax Expense 0 0 0 -237
Net Income -54,067,346 -430,183 -354,310 -358,578
Per Share
EPS -12.50 -32.23 -287.82 -95.95
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Revenue 0 0 0 0 0
Cost of Revenue 0 21,656 17,760 28,366 0
Gross Profit 0 -21,656 -17,760 -28,366 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 0 1,288,000 1,511,000 1,734,818 1,581,187
Operating Expenses 57,278,131 1,514,000 1,759,000 1,990,870 1,812,143
Operating Income -57,278,131 -1,536,000 -1,777,000 -1,990,870 -1,812,143
Interest Expense 563,757 665,841 532,821 568,798 449,457
Income Before Tax -58,923,300 -1,950,000 -2,790,000 -2,713,064 -2,139,362
Income Tax Expense 0 -129,000 -130,000 -54,977 -113,415
Net Income -58,923,300 -1,821,000 -2,661,000 -2,658,087 -2,025,947
Per Share
EPS -14.85 -1,420.95 -31,268.39 -1.53 -0.80
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Assets
Cash and Cash Equivalents 12,088 21,085 10,047 4,067
Short Term Investments 0 0 0 0
Net Receivables 0 2,950 2,867 2,342
Inventory 0 0 -2,867 0
Total Current Assets 8,352,816 25,441 19,039 15,030
Property Plant Equipment 59,413 17,799 39,290 64,546
Goodwill and Intangibles 0 0 0 0
Total Assets 19,631,808 72,365 60,328 81,651
Liabilities
Account Payables 1,249,596 1,213,335 966,718 943,023
Short Term Debt 1,098,897 889,629 526,638 1,056,036
Total Current Liabilities 5,578,240 3,792,782 3,158,229 3,062,981
Long Term Debt 147,376 58,642 19,278 42,319
Total Liabilities 5,725,616 3,851,424 3,177,507 3,105,300
Shareholders Equity
Retained Earnings -125,621,520 -66,698,220 -64,684,732 -61,557,893
Total Shareholders Equity 13,906,192 -3,779,059 -3,117,179 -3,023,649
Balance Sheet (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Assets
Cash and Cash Equivalents 12,088 21,085 10,047 4,067 2,255
Short Term Investments 0 0 0 0 0
Net Receivables 0 2,950 2,867 2,342 4,341
Inventory 0 0 -2,867 0 0
Total Current Assets 8,352,816 25,441 19,039 15,030 6,596
Property Plant Equipment 59,413 17,799 39,290 64,546 4,255
Goodwill and Intangibles 0 0 0 0 0
Total Assets 19,631,808 72,365 60,328 81,651 13,101
Liabilities
Account Payables 1,249,596 1,213,335 966,718 943,023 1,002,335
Short Term Debt 1,098,897 889,629 526,638 1,056,036 680,083
Total Current Liabilities 5,578,240 3,792,782 3,158,229 3,062,981 3,080,674
Long Term Debt 147,376 58,642 19,278 42,319 0
Total Liabilities 5,725,616 3,851,424 3,177,507 3,105,300 3,080,674
Shareholders Equity
Retained Earnings -125,621,520 -66,698,220 -64,684,732 -61,557,893 -58,199,466
Total Shareholders Equity 13,906,192 -3,779,059 -3,117,179 -3,023,649 -3,067,573
Cash Flow Statement (Quarterly) 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Activities
Net Income -58,923,300 -1,820,528 -2,660,566 -2,658,087
Depreciation & Amortization 4,641,417 21,656 22,931 5,671
Stock Based Compensation 0 0 141,356 387
Change in Working Capital 0 417,418 472,587 167,435
Operating Cash Flow -405,168 -935,118 -1,105,251 -1,436,304
Investing Activities
Capital Expenditure 0 -2 0 0
Investments 0 0 0 0
Investing Cash Flow 0 0 0 0
Financing Activities
Debt Repayment 0 918,837 -590,250 -766,500
Common Stock Issued/Repurchased 51,348,000 23,057 499,711 -667,215
Dividends Paid 0 0 -466,273 -700,340
Financing Cash Flow 490,756 941,894 1,113,719 1,490,786
Summary
Free Cash Flow -405,168 -935,118 -1,105,251 -1,436,304
Net Change in Cash -8,997 11,038 5,980 1,812
Cash Flow Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Operating Activities
Net Income -58,923,300 -1,820,528 -2,660,566 -2,658,087 -2,025,947
Depreciation & Amortization 4,641,417 21,656 22,931 5,671 1,993
Stock Based Compensation 0 0 141,356 387 82,872
Change in Working Capital 0 417,418 472,587 167,435 439,046
Operating Cash Flow -405,168 -935,118 -1,105,251 -1,436,304 -1,145,264
Investing Activities
Capital Expenditure 0 -2 0 0 0
Investments 0 0 0 0 0
Investing Cash Flow 0 0 0 0 0
Financing Activities
Debt Repayment 0 918,837 -590,250 -766,500 -43,000
Common Stock Issued/Repurchased 51,348,000 23,057 499,711 -667,215 0
Dividends Paid 0 0 -466,273 -700,340 0
Financing Cash Flow 490,756 941,894 1,113,719 1,490,786 1,058,044
Summary
Free Cash Flow -405,168 -935,118 -1,105,251 -1,436,304 -1,145,264
Net Change in Cash -8,997 11,038 5,980 1,812 -64,752